Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

(2010) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials

(2010) Belinda E. Kiely et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic inflammation, nutritional status and survival in patients with cancer

(2009) Donald C McMillan   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment

(2008) HanByoul Cho et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

(2008) A. M. Schultheis et al.   CLINICAL CANCER RESEARCH

Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer

(2008) Rohini Sharma et al.   EUROPEAN JOURNAL OF CANCER

Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer

(2008) Gabriella Ferrandina et al.   GYNECOLOGIC ONCOLOGY

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer

(2007) S. Bishara et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology